Physician profile
Steven Yang
NPI 1518173913
$4,091.28
in general payments reported to CMS, 2019-2025
25 companies · $704 in 2025
The $704 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $739 · 2021: $504 · 2022: $470 · 2023: $642 · 2024: $673 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.81 |
| Education | $107.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $616.46 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $545.15 | 2019-2025 | Ubrelvy |
| Amgen INC. | $405.62 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $367.99 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $345.83 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $307.99 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $297.37 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $197.46 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $185.05 | 2019-2025 | Verquvo, Capvaxive, Steglatro |
| Allergan, INC. | $172.18 | 2019-2020 | |
| Lilly USA, LLC | $158.71 | 2023-2024 | Mounjaro, Zepbound |
| Arbor Pharmaceuticals, INC. | $68.07 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $53.99 | 2023 | Edarbi |
| Exact Sciences Corporation | $50.89 | 2023-2025 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $36.01 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $35.07 | 2020-2022 | |
| Mylan Specialty L.P. | $34.06 | 2019-2021 | |
| Sanofi Pasteur INC. | $33.72 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.13 | 2019-2020 | |
| Alk-Abello, INC | $25.62 | 2025 | Odactra, Grastek, Ragwitek |
| Endo Pharmaceuticals INC. | $24.93 | 2021 | |
| Boston Scientific Corporation | $23.66 | 2020 | |
| Corium, LLC | $23.44 | 2023 | Azstarys |
| Organogenesis INC. | $22.96 | 2025 | Puraply Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.